🔎 Trials Near Me

መነሻ › አልሰራቲቭ ኮላይቲስ › Utah

በUtah ለአልሰራቲቭ ኮላይቲስ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአልሰራቲቭ ኮላይቲስ የሚደረጉ 7 ጥናቶች በUtah ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በUtah ውስጥ ያሉ ከተሞች

Official study text (English)

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  • Care Access-Ogden, Ogden
  • Advanced Research Institute - South Ogden, Ogden
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06598943

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • University of Utah Hospitals & Clinics, Salt Lake City
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06979336

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • University of Utah, Salt Lake City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 3 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06663332

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  • Care Access - Ogden, Ogden
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07186101

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • University of Utah Health, Salt Lake City
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06095128

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Velocity Clinical Research, Salt Lake City - Site Number: 8400147, West Jordan
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ16 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07184996

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  • University of Utah Health, Salt Lake City
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05230173

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።